MARKET WIREYahoo! Finance Canada • 6h ago
Sol-Gel Technologies Ltd. (SLGL) Stock Price, News, Quote & HistoryYahoo! Finance Canada report covering Sol-Gel Technologies Ltd. (SLGL) market action, institutional positioning, and fundamental catalysts.
Why SLGL Stock slipped -0.45% Today — RQD Quant Desk Flash
$68.35 -0.45% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $68.16
Sol-Gel Technologies Ltd. (SLGL) carries a Roarable Rating of D+ (Sell) with 54/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D+ • SELL / AVOID
Cap $224.8M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on SLGL Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is SLGL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Sol-Gel Technologies Ltd. (NASDAQ: SLGL) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $68.35 (-0.45% 1D, market cap $224.8M). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, SLGL ranks #247 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does SLGL compare to KROS and PYXS in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SLGL carries a Roarable D+ (54/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, KROS (Keros Therapeutics Inc.) holds a C+ grade (66/100 RQD, P/E N/A, ROIC 85.0%, cap $225.2M) and PYXS (Pyxis Oncology Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $226.0M). Among the 5-stock peer group, SIGA leads on earnings multiple (9.8x) while KROS leads on capital efficiency (85.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for SLGL?
▼
Per SLGL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001684693), Sol-Gel Technologies Ltd. generated $19.4M in revenue (+68.0% YoY), -$6.1M in net income, and $275.0K in free cash flow against $29.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $68.17 (-0.27%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 1.4% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 54/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.7% avg 90D alpha vs SPY • 51.0% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D+
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D · Rk C+
Each axis scored 0–20
12M PRICE TARGET CONE-1.8% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SLGL)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (54/100 Composite)
🔍 WHY SLGL SCORES 54/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (26% of score)
Altman Z-Score 8.54 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 6/9
▲ #2 Bullish Driver: Cash Engine Quality+13/20 pts (24% of score)
SEC XBRL FY 2025 (10-K): 1.4% FCF Margin ($275.0K FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C+$72.40-10.2% Next Q
62
Q2 (-2Q)Grade C$64.98+7.2% Next Q
59
Q3 (-1Q)Grade C$69.63-1.8% Next Q
57
CurrentGrade D+$68.35-0.7% Hist 90D α
54
Trajectory: C+ (62) → D+ (54)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a SLGL Turnaround Squeeze
While SLGL currently carries a cautious 54/100 (D+) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($68.78) and Max Pain ($71.77) forces dealer call-delta covering toward $102.87.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $SLGL• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “SLGL Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why SLGL Stock slipped -0.45% Today — RQD Quant Desk Flash
Sol-Gel Technologies Ltd. (SLGL) slipped -0.45% to $68.35, trading at 57% of its 52-week range ($28.81 – $97.97). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 57% of its 52-week range ($28.81 – $97.97) with RSI-14 at 41.5 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $68.35 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D+ (Sell) backed by 52% gross margin and $275000 annual free cash flow.
Live SLGL Headlines & Catalysts
MARKET WIRESeeking Alpha • 9h ago
Sol-Gel Technologies Ltd. (SLGL) Analyst/Investor Day - Slideshow (NASDAQ:SLGL) 2026-10-15Seeking Alpha report covering Sol-Gel Technologies Ltd. (SLGL) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 12h ago
HC Wainwright & Co. reiterates Buy rating on Sol-Gel Technologies, $110 price targetTradingView report covering Sol-Gel Technologies Ltd. (SLGL) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvesting.com • 15h ago
H.C. Wainwright reiterates Sol Gel stock rating ahead of trial dataInvesting.com report covering Sol-Gel Technologies Ltd. (SLGL) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 18h ago
A fund reports 166,473 shares in Sol-Gel Technologies (SLGL), exceeding 5% ownership.Stock Titan report covering Sol-Gel Technologies Ltd. (SLGL) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 21h ago
New Strong Buy Stocks for October 16thYahoo Finance report covering Sol-Gel Technologies Ltd. (SLGL) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 1d ago
SLGL - Phase 3 Gorlin Syndrome Catalyst Will Reshape Orphan Dermatology Outlook For This BusinessSimply Wall St report covering Sol-Gel Technologies Ltd. (SLGL) market action, institutional positioning, and fundamental catalysts.
CATALYSTBenzinga • 1d ago
This Entegris Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For WednesdayBenzinga report covering Sol-Gel Technologies Ltd. (SLGL) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo • 3d ago
Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue EstimatesSupernus (SUPN) delivered earnings and revenue surprises of +89.80% and +1.39%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
MARKET WIREBenzinga • 14d ago
HC Wainwright & Co. Reiterates Buy on Sol-Gel Technologies, Maintains $110 Price TargetHC Wainwright & Co. analyst Raghuram Selvaraju reiterates Sol-Gel Technologies (NASDAQ:SLGL) with a Buy and maintains $110 price target.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SLGL)
- ✓Walkthrough of SLGL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
SLGL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -12.03%▼ DESCENDING CHANNEL
2026-11-02O $67.29H $68.35L $64.55C $68.35VOL 29.4K
RES: $74.40SUP: $53.03SMA50: $68.78SMA200: $74.02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
SLGL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +68.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on SLGL today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for SLGL. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SLGL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SLGL)
Health Care Rank #247 of 1016
⚔️ KROS vs SLGL Full Matrix →
1. Head-to-Head Health Care Peer Comparison (SLGL vs. KROS, PYXS, SIGA, BBOT)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Sol-Gel Technologies Ltd. (SLGL) ranks #247 by composite RQD confidence (54/100, grade D+) and #562 by equity capitalization ($224.8M). Within this direct 5-issuer industry benchmark cohort, SIGA leads on earnings valuation at 9.8x trailing P/E, while KROS leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. SIGA currently holds the highest overall quantitative score in the immediate peer group at 72/100 (B) compared with SLGL at 54/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SLGL
ACTIVE
Sol-Gel Technologies Ltd. | D+ | 54/100 | — | — | -35.0% | -0.45% | $224.8M | Benchmark Subject |
| KROS Keros Therapeutics Inc. | C+ | 66/100 | — | — | 85.0% | -2.82% | $225.2M | /kros-vs-slgl → |
| PYXS Pyxis Oncology Inc. | E | 29/100 | — | 82.8% | -35.0% | -4.23% | $226.0M | /pyxs-vs-slgl → |
| SIGA SIGA Technologies Inc. | B | 72/100 | 9.8x | 68.6% | 42.7% | -4.40% | $228.5M | /siga-vs-slgl → |
| BBOT BridgeBio Oncology Therapeutics Inc. | D- | 37/100 | — | — | -35.0% | -2.96% | $216.5M | /bbot-vs-slgl → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001684693In its most recent audited fiscal period (FY2025, filed 2025-12-31), Sol-Gel Technologies Ltd. (SLGL) reported GAAP revenue of $19.4M (+68.0% vs. FY2024 revenue of $11.5M , and +1147.6% cumulative change since FY2023) , GAAP net income of -$6.1M, operating cash flow of $322.0K, and free cash flow of $275.0K (+102.0% YoY). On the balance sheet, SLGL closed FY2025 with $29.9M in total assets against $0 in total debt (Altman Z-Score: 8.54, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $19.4M | -$6.1M | $322.0K | $275.0K | $29.9M | — |
| FY2024 (FY) | 2024-12-31 | $11.5M | -$10.6M | -$13.9M | -$13.9M | $35.8M | — |
| FY2023 (FY) | 2023-12-31 | $1.6M | -$27.2M | -$17.7M | -$17.7M | — | — |
3. SLGL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs SLGL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Sol-Gel Technologies Ltd. (NASDAQ: SLGL) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $68.35 (-0.45% 1D, market cap $224.8M). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, SLGL ranks #247 in composite RQD confidence.
How does SLGL compare to KROS and PYXS in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SLGL carries a Roarable D+ (54/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, KROS (Keros Therapeutics Inc.) holds a C+ grade (66/100 RQD, P/E N/A, ROIC 85.0%, cap $225.2M) and PYXS (Pyxis Oncology Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $226.0M). Among the 5-stock peer group, SIGA leads on earnings multiple (9.8x) while KROS leads on capital efficiency (85.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for SLGL?
Per SLGL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001684693), Sol-Gel Technologies Ltd. generated $19.4M in revenue (+68.0% YoY), -$6.1M in net income, and $275.0K in free cash flow against $29.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is SLGL trading relative to its 50-day, 200-day, and 52-week technical levels?
SLGL last traded at $68.35 (-0.45% on volume of 33,525 shares), positioning the stock -0.63% below its 50-day simple moving average ($68.78) and -7.66% below its 200-day simple moving average ($74.02). Across its 52-week range of $28.81 to $97.97, SLGL sits at the 57.2% percentile with a 14-day RSI of 41.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($59.81 to $76.89).
SLGL Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is SLGL stock moving today?
Why SLGL Stock slipped -0.45% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 54/100 (D+)
✓ STAGE-C NUMBER FIREWALL VERIFIED
SLGL — Sol-Gel Technologies Ltd.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:40:37Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, SLGL scores 54 out of 100, a D+ grade labeled "Roarable Sell — Weak Fundamentals / Trim." The five pillars are: Fundamental Cash Engine 13/20 (reflecting ROIC of -35% and FCF yield of 0.12%); Whale 13F Flow 9/20 (institutional accumulation and options positioning); Insider Conviction 5/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit 13/20 (Beta of 1.0 and sector sensitivity); and Forensic Balance Sheet 14/20 (Altman Z 8.54, Piotroski F 6/9, Debt/Equity 0.5). For a prospective investor, the weakest pillar is insider conviction, while the cash engine and macro-fit pillars also score in the lower range. The forensic balance sheet metrics are the relative strength within the rating: a high Altman Z and Debt/Equity of 0.5 indicate balance sheet resilience even as operating economics remain negative. Valuation tradeoffs cannot be fully assessed because P/E and EV/EBITDA are not available in source data; the stock's position within its 52-week range of $59.43 - $74.54 at a price of 68.66 is therefore the only valuation reference available.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $19.4M | $-7.5M | $-6.1M | N/A | $0.3M | $11.0M | N/A |
| FY 2024 | $11.5M | $-12.0M | $-10.6M | N/A | $-13.9M | $19.5M | N/A |
| FY 2023 | $1.6M | $-29.3M | $-27.2M | N/A | $-17.7M | N/A | N/A |
Per the SEC financials, revenue rose from $1.6M in FY 2023 to $19.4M in FY 2025 while operating losses narrowed from $-29.3M to $-7.5M. Per market data, the operating margin is -38.9%, the net margin is -31.6%, and gross margin is 0%. ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 8.54 and the Piotroski F-Score is 6/9, with Debt/Equity at 0.5. FY 2025 cash is $11.0M, down from $19.5M in FY 2024.
Recent Catalysts & News Wire Analysis
Per the recent news feed, the catalysts are headline-level only, all tagged as market wire items: a Yahoo! Finance Canada stock page, a Seeking Alpha item referencing an Analyst/Investor Day slideshow dated 2026-10-15, a TradingView item reporting HC Wainwright & Co. reiterating a Buy rating with a $110 price target, an Investing.com item reporting HC Wainwright reiterating ahead of trial data, a Stock Titan item reporting a fund holding 166,473 shares exceeding 5% ownership, and a Yahoo Finance "New Strong Buy Stocks" listing. Risk watch items include the pending trial data referenced in the news and the negative margin profile. Per the Butterfly Supply-Chain Graph, supply chain is NONE, with no butterfly links and no proprietary signals.
Open Questions
- What are the company's products, customers, and revenue drivers, given that the source data does not describe them?
- What is the outcome and timing of the trial data referenced in the news, and how would it affect revenue and cash?
- What is the FY 2025 debt balance, since the source lists debt as N/A?
- What is the basis for the weak insider conviction score, and what specific Form 4 or Congressional transactions drove it?
- What is the EPS and valuation multiple profile, given that P/E, EV/EBITDA, and EPS are unavailable?
SLGL Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Sol-Gel Technologies Ltd. (SLGL) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo! Finance Canada • 6h ago
Sol-Gel Technologies Ltd. (SLGL) Stock Price, News, Quote & History Yahoo! Finance Canada report covering Sol-Gel Technologies Ltd. (SLGL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Seeking Alpha • 9h ago
Sol-Gel Technologies Ltd. (SLGL) Analyst/Investor Day - Slideshow (NASDAQ:SLGL) 2026-10-15 Seeking Alpha report covering Sol-Gel Technologies Ltd. (SLGL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 12h ago
HC Wainwright & Co. reiterates Buy rating on Sol-Gel Technologies, $110 price target TradingView report covering Sol-Gel Technologies Ltd. (SLGL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com • 15h ago
H.C. Wainwright reiterates Sol Gel stock rating ahead of trial data Investing.com report covering Sol-Gel Technologies Ltd. (SLGL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 18h ago
A fund reports 166,473 shares in Sol-Gel Technologies (SLGL), exceeding 5% ownership. Stock Titan report covering Sol-Gel Technologies Ltd. (SLGL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 21h ago
New Strong Buy Stocks for October 16th Yahoo Finance report covering Sol-Gel Technologies Ltd. (SLGL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 1d ago
SLGL - Phase 3 Gorlin Syndrome Catalyst Will Reshape Orphan Dermatology Outlook For This Business Simply Wall St report covering Sol-Gel Technologies Ltd. (SLGL) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Benzinga • 1d ago
This Entegris Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday Benzinga report covering Sol-Gel Technologies Ltd. (SLGL) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
SLGL Bull vs. Bear Conversation Board — What's Your Call at $68.35?
🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SLGL 🐻 50% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST
🎯 Target: $74.15 (+8.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is SLGL (D+ • RQD 54/100) a Buy at $68.66?
Welcome to the SLGL (Sol-Gel Technologies Ltd.) Roar Pit. Current RQD Composite is 54/100 (Roarable Sell — Weak Fundamentals / Trim) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $55.61 (-19.0%)
Spot @ $68.66 Pump the brakes on SLGL — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on SLGL, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Sol-Gel Technologies Ltd. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH
🎯 Target: $83.77 (+22.0%)
Spot @ $68.66 SLGL cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on SLGL, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $68.66 (52-wk range $59.43 - $74.54), any beat on forward guidance forces shorts and underweight funds to chase.